FDA Approves New Obesity Pill Foundayo, Offering Patients Another Option

The daily pill from Eli Lilly will compete with Wegovy's pill form as an alternative to injectable obesity drugs.

Apr. 1, 2026 at 8:07pm

Got story updates? Submit your updates here. ›

The FDA has approved a new obesity pill called Foundayo from drugmaker Eli Lilly. The once-daily pill will compete with the pill form of Wegovy, made by Novo Nordisk, which was approved in December. Patients now have a choice between pills instead of injections for the leading obesity medicines. The FDA approved Foundayo on a fast track, taking just 50 days, the fastest for a brand-new drug since 2002.

Why it matters

The new pill options could appeal to many patients who may be hesitant about taking injectable obesity drugs. However, the cost of the medications and limits on insurance coverage remain obstacles for patients seeking these treatments.

The details

Foundayo uses a new active ingredient called orforglipron that is easier for the body to absorb in pill form, unlike the injectable obesity drugs which use peptides. In clinical trials, patients taking the highest dose of Foundayo lost an average of 27.3 pounds, or 12.4% of their body weight, compared to 2.2 pounds, or 0.9%, for those taking a placebo. The most common side effects were nausea, constipation and diarrhea.

  • The FDA approved Foundayo on April 1, 2026.
  • Wegovy's pill form was approved by the FDA in December.

The players

Eli Lilly

The pharmaceutical company that developed the new obesity pill Foundayo.

Novo Nordisk

The maker of the Wegovy injectable obesity drug, which also has a pill form that will compete with Foundayo.

Daniel Skovronsky

Eli Lilly's chief scientific and product officer, who says the new Foundayo pill is more convenient than injectable obesity drugs.

Dr. Catherine Varney

The obesity medicine director for UVA Health in Charlottesville, Virginia, who says the new pill may have an advantage in the real world due to its easier dosing.

Jamey Millar

The executive vice president for U.S. operations of Novo Nordisk, who disputed claims that Foundayo is more effective than Wegovy's pill.

Got photos? Submit your photos here. ›

What they’re saying

“We've created a small molecule chemical which gets in your body very well. It can mimic the effects of the peptide and can be taken more conveniently any time of day without any food or water restrictions.”

— Daniel Skovronsky, Chief Scientific and Product Officer, Eli Lilly

“Not all GLP-1s are the same. Any reports claiming orforglipron is more effective than Wegovy pill for weight management are inaccurate and misleading.”

— Jamey Millar, Executive Vice President for U.S. Operations, Novo Nordisk

“I can tell you of over the 1,000 patients that I have on GLP-1 therapy, not once has needle phobia been an issue.”

— Dr. Catherine Varney, Obesity Medicine Director, UVA Health

What’s next

Lilly says its insurance coverage plans for Foundayo will become clearer soon, and starting in July, people with Medicare coverage may be able to get the pill for $50 a month. Medicaid coverage could take some more time to be determined.

The takeaway

The approval of Foundayo provides patients with another option for obesity treatment beyond injectable drugs, but cost and insurance coverage remain key barriers to access. The convenience of a daily pill may give Foundayo an advantage, though the long-term real-world effectiveness compared to other GLP-1 medications is still to be determined.